Endocrine resistance in breast cancer – An overview and update
Authors:
- 1 December 2015
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 418, 220-234
Abstract
No abstract availableKeywords
Funding Information
- US Public Health Service National Cancer Institute (U01-CA184902, U54-CA149147, P30-CA51008)
This publication has 204 references indexed in Scilit:
- Dynamic modelling of oestrogen signalling and cell fate in breast cancer cellsNature Reviews Cancer, 2011
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitorsProceedings of the National Academy of Sciences, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- PIK3CAmutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancerProceedings of the National Academy of Sciences, 2010
- Activation and clinical significance of the unfolded protein response in breast cancerBritish Journal of Cancer, 2009
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- The properties of high-dimensional data spaces: implications for exploring gene and protein expression dataNature Reviews Cancer, 2008
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971